G

Galecto
D

GLTO

4.64000
USD
0.05
(1.09%)
مغلق
حجم التداول
15
الربح لكل سهم
-16
العائد الربحي
-
P/E
-0
حجم السوق
6,110,829
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADMA
    -0.238
    (-1.48%)
    15.835 USD
    A
    ARDX
    -0.65000
    (-11.39%)
    5.05500 USD
    B
    BPMC
    -2.080
    (-2.20%)
    92.280 USD
    C
    CKPT
    -0.05000
    (-1.57%)
    3.13000 USD
    KHC
    KHC
    0.985
    (3.27%)
    31.140 USD
    K
    KOD
    -0.29500
    (-6.23%)
    4.44000 USD
    M
    MGNX
    -0.13000
    (-4.50%)
    2.76000 USD
    N
    NVCR
    0.420
    (1.94%)
    22.090 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    المزيد
الأخبار
المقالات

العنوان: Galecto Inc

القطاع: Healthcare
الصناعة: Biotechnology
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.